價格 | ¥265 | ¥379 | ¥659 |
包裝 | 5mg | 10mg | 25mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-07-28 |
中文名稱:左布比卡因 | 英文名稱:Levobupivacaine |
CAS:27262-47-1 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
純度規(guī)格: 99.72% | 產(chǎn)品類別: 抑制劑 |
貨號: T1787 |
名稱 | Levobupivacaine |
描述 | Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
溶解度 | DMSO : 6 mg/mL (20.8 mM), Sonication is recommended. |
關(guān)鍵字 | SodiumChannel | Sodium Channel | NMDA | Na+ channels | Na channels | Levobupivacaine | Inhibitor | inhibit | gastric cancer | Ferroptosis | Erastin | CYP450 | CNS toxicity | cardiac toxicity | analgesic | anaesthetic |
相關(guān)產(chǎn)品 | Lidocaine hydrochloride | Benzocaine | Valproic Acid | Lidocaine | Mebeverine hydrochloride | Safinamide | Procaine | Amitriptyline hydrochloride | L-Aspartic aicd sodium | Lidocaine Hydrochloride hydrate | Riluzole | Phenytoin sodium |
相關(guān)庫 | 神經(jīng)保護(hù)化合物庫 | 經(jīng)典已知活性庫 | 抗癌上市藥物庫 | 已知活性化合物庫 | 藥物片段庫 | FDA 上市藥物庫 | 離子通道庫 | 膜蛋白靶向化合物庫 | 藥物功能重定位化合物庫 | 疼痛相關(guān)化合物庫 | 兒童藥物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (13年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
普善實業(yè)(陜西)有限公司
|
2025-08-06 | |
詢價 |
VIP9年
|
凱立德生物醫(yī)藥技術(shù)(上海)有限公司
|
2025-08-06 | |
詢價 |
VIP6年
|
武漢欣揚(yáng)瑞和化學(xué)科技有限公司
|
2025-08-05 | |
詢價 |
VIP3年
|
陜西締都新材料有限公司
|
2025-07-09 | |
詢價 |
VIP1年
|
廣州佳途科技股份有限公司
|
2025-07-01 | |
¥720.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2025-05-16 | |
詢價 |
南京道格生物醫(yī)藥科技有限公司
|
2022-10-22 | ||
詢價 |
山東濟(jì)南市匯豐達(dá)化工有限公司
|
2020-03-30 |